John Maraganore

@JMaraganore

CEO of . Developing RNAi therapeutics - an innovative new class of medicines, to improve lives of patients. Opinions are my own.

Cambridge, MA
Vrijeme pridruživanja: lipanj 2017.

Tweetovi

Blokirali ste korisnika/cu @JMaraganore

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @JMaraganore

  1. prije 6 sati

    Regardless of your view on impeachment, showed great patriotism today to honor his oath and constitutional responsibility over his party. History will look v. kindly on him!

    Poništi
  2. 5. velj

    Truly remarkable interview with E. Braunwald, a legend of modern cardiology and medicine. From Nazi-occupies Austria to Brooklyn... story of an immigrant who came from nothing to become a national treasure! Thanks for sharing !

    Poništi
  3. 4. velj

    Another example of responding to an industry “call to arms” in the fight against #2019-nCoV.... and another reason to be proud and thankful of America’s industry! Thank you,

    Poništi
  4. proslijedio/la je Tweet

    Deerfield’s Alex Karnal is absolutely right: adopting foreign price controls “prevents investors from being able to invest, and inventors from being able to invent.”

    Poništi
  5. proslijedio/la je Tweet
    3. velj

    26 days until ! But for the >300 million people worldwide living w/ a , their families, friends, caregivers & healthcare professionals and those focused on developing new treatments, every day is rare disease day. Learn more about how to !

    Poništi
  6. 31. sij

    Gr8 to see from our industry being applied to a major global public health emergency. So important to remember this when some demonize our industry! Thank you !!

    Poništi
  7. proslijedio/la je Tweet
    31. sij

    We’re pleased to announce that we’ve received a positive opinion from the EMA () Committee for Medicinal Products for Human Use () for our investigational therapeutic for the treatment of the acute hepatic .

    Poništi
  8. 30. sij

    So happy for my friend and his wife Julia, who will now get him 24/7! Thanks Steve for your many years of leadership in and for championing and change!

    Poništi
  9. proslijedio/la je Tweet
    29. sij

    Kudos to for RxZERO (no OOP for drugs) This is a broken market! - Drugs sold to at -54% discount 😲 - "clients opt to keep rebates" 🙄 - Patients pay OOP on pre-rebate list price & are less adherent 🙁

    Poništi
  10. 29. sij

    Thanks and for highlighting the story as one of the successes in the Boston/Cambridge ecosystem! There is no better place in the world to make a medicine than right here!

    Poništi
  11. 27. sij
    Poništi
  12. 26. sij

    For “haute science and innovation,” Kendall Sq is where it’s at! Not cheap, but you sort of get what you pay for when it comes to people and culture.

    Poništi
  13. 25. sij

    Completely agree ! is flawed by not accounting for generics. The medicines we pay for today are essentially free for our kids and grandkids!

    Poništi
  14. 24. sij

    This is awesome! How about other investment banks doing this also? Let’s all ask our banker friends to follow suit. Time for change!

    Poništi
  15. proslijedio/la je Tweet

    Congratulations to upon his election for a second term as president of ! We are so excited to continue our work under his leadership.

    Poništi
  16. 23. sij

    Thanks for sharing these deeply personal thoughts! Hatred and bigotry have no place in this world. Imagine a society that embraces tolerance! So simple, yet powerful.

    Poništi
  17. 21. sij

    Great interview with ! Such an inspiring leader and legend in our industry!

    Poništi
  18. 20. sij

    Remembering , some powerful words for today’s world: “Darkness cannot drive out darkness; only light can do that. Hate cannot drive out hate; only love can do that.”

    Poništi
  19. 20. sij

    Important point here on vs. SMs and Mabs: clamped PD vs. peak-trough PD can result in better outcomes. Similar approach as w/ LDL now being applied to blood pressure, trigs, and more.

    Poništi
  20. proslijedio/la je Tweet

    Provocative insight from excellent Bernstein Research: Medicaid is highly incentivized to stick with older branded biologics because of heavy rebates on incumbents that can make them virtually free, and has little to no incentive to adopt biosimilars—frustrating low cost entrants

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·